Skip to main
GRI

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc demonstrates a strong positive outlook due to its innovative therapeutic approach targeting serious immune-related diseases, supported by compelling clinical data and an attractive current valuation. The company’s lead candidate, GRI-0621, has shown improvement in key serum biomarkers related to fibrosis and effective lung function outcomes, indicating potential therapeutic benefits and favorable safety profiles. Additionally, ongoing valuation assessments suggest significant upside potential from its current share price, reflecting a balanced approach considering the inherent risks and rewards in the biotech sector.

Bears say

GRI Bio Inc reported a net loss of $3.4 million or EPS of $(1.28), which fell short of both internal estimates and consensus expectations, indicating financial underperformance. Furthermore, the company faces significant risks, including potential failures of its product candidates during clinical trials, regulatory approval challenges, and issues related to commercialization and reimbursement, which could further exacerbate its financial instability. Additionally, with both product candidates still in the early phases of development, the lengthy timelines and high unpredictability surrounding clinical trials add considerable uncertainty regarding future revenue generation and overall financial health.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.